Highbridge Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Highbridge Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,335	Closed	-$165K	–	1702
2017 Q1	$165K	Sell	1,335 -3,137	-70%	-$411K	﹤0.01%	1342
2016 Q4	$609K	Buy	+4,472	New	+$794K	0.01%	700
2015 Q4	–	Sell	-2,796	Closed	-$406K	–	1890
2015 Q3	$406K	Buy	+2,796	New	+$513K	0.01%	1118

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Highbridge Capital Management's BLCM Position: Q2 2017 in Review

Highbridge Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2017, closing a stake of 1,335 shares — an estimated $165K sold.

Highbridge Capital Management first reported a position in BLCM in Q3 2015 and held it in 3 quarters. The position peaked at $609K in Q4 2016. 84 funds tracked by Wall St. Rank hold BLCM as of Q2 2017.

Highbridge Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 1,335 Bellicum Pharmaceuticals, Inc. shares in Q2 2017, an estimated $165K.
Highbridge Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
Highbridge Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $609K in Q4 2016.
84 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.